-
摘要:
随着胃镜和结肠镜使用的普及，胃肠胰腺神经内分泌肿瘤（gastroenteropancreatic neuroendocrine neoplasm, GEP-NEN）的检出率逐年升高。近年来，从疾病术语、诊断到治疗方案都发生了较大的变化。目前，单一治疗手段已经无法给患者带来最大获益，多学科综合诊疗模式对于推动和规范GEP-NEN的诊疗具有重要意义。本文对相关文献进行复习并基于国内外最新共识（2017年）对这一类疾病进行综述，以增加对胃肠胰神经内分泌肿瘤的认识，为未来大样本的临床诊断、治疗和预后研究奠定基础。
Abstract:With the extensive use of gastroscopy as well as colonoscopy, the detectable rate of gastroenteropancreatic neuroendocrine neoplasm(GEP-NEN) has increased substantially. In recent years, the nomination, diagnosis and management of GEP-NEN have changed tremendously. Nowadays, the single-mode treatment is unable to bring the greatest benefit to patients. Instead, multidisciplinary comprehensive treatment model for the promotion and regulation of GEP-NEN diagnosis and treatment is of great significance. This paper is an overview of the related articles and latest clinical consensus(2017) both at home and abroad, which improves the identification of these rare tumors. Additionally, it lays the foundation for clinical diagnosis, treatment as well as prognosis of large sample in future.
-
Key words:
- Gastroenteropancreatic neoplasm /
- Neuroendocrine tumor /
- Diagnosis /
- Treatment
-
-
表 1 NCCN（2017年）肿瘤学临床实践指南与WHO（2010年）关于胃肠胰腺神经内分泌肿瘤分级标准对比结果
Table 1 Comparison of gastrointestinal pancreatic neuroendocrine tumor grading standards between NCCN (2017) Oncology Clinical Practice Guidelines and WHO (2010)
下载: 导出CSV
-
[1] Lüttges J. What's new? The 2010 WHO classification for tumours of the pancreas[J]. Pathologe, 2011, 32 Suppl 2: 332-6. http://surgpathcriteria.stanford.edu/pancreas/intraductal_oncocytic_papillary_neoplasm/printable.html
[2] Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas[J]. Neuroendocrinology, 2016, 103(2): 186-94. doi: 10.1159/000443172
[3] 中国胃肠胰神经内分泌肿瘤病理诊断共识专家组.中国胃肠胰神经内分泌肿瘤病理诊断共识(2013版)[J].中华病理学杂志, 2013, 42(10): 691-4. doi: 10.3760/cma.j.issn.0529-5807.2013.10.011 Expert Group of Pathology Diagnosis of Gastrointestinal Pancreatic Neuroendocrine Tumors in China. Chinese gastrointestinal pancreatic neuroendocrine tumor pathology diagnosis consensus (2013 version)[J]. Zhonghua Bing Li Xue Za Zhi, 2013, 42(10): 691-4. doi: 10.3760/cma.j.issn.0529-5807.2013.10.011
[4] NCCN. NCCN clinical practice guidelines in oncology Neuroendocrine Tumors (2017. V3) [S/OL]. 2017-06-14]. http://cache1.medsci.cn/webeditor/uploadfile/201706/20170615141559643.pdf.
[5] 李剑昂, 韩序, 方圆, 等.胃神经内分泌肿瘤的临床病理特征及根治性手术后预后分析[J].中国实用外科杂志, 2013, 33(10): 866-70. http://www.cqvip.com/QK/90965A/201310/47456421.html Li JA, Han X, Fang Y, et al. A study of clinical characteristics and prognostic factors 49 patients with gastric neuroendocrine neoplasms treated with radical surgery[J]. Zhongguo Shi Yong Wai Ke Za Zhi, 2013, 33(10): 866-70. http://www.cqvip.com/QK/90965A/201310/47456421.html
[6] 曹晖, 赵文毅.应该重视特殊类型的胃肿瘤[J].中华胃肠外科杂志, 2013, 16(2): 128-31. http://news.medlive.cn/cancer/info-progress/show-73064_53.html Cao H, Zhao WY. Emphasis on special types of stomach tumors[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2013, 16(2): 128-31. http://news.medlive.cn/cancer/info-progress/show-73064_53.html
[7] 刘丹, 沈琳, 陆明.胃神经内分泌肿瘤的诊断和治疗[J].临床肿瘤学杂志, 2015, 20(6): 549-50. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhlcyszz201422002 Liu D, Shen L, Lu M. Diagnosis and treatment for gastric neuroendocrine tumors[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2015, 20(6): 549-50. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhlcyszz201422002
[8] 《肿瘤病理诊断规范》项目组.肿瘤病理诊断规范(胃肠胰神经内分泌肿瘤)[J].中国病理学杂志, 2017, 46(2): 76-8. http://guide.medlive.cn/guideline/12698 Panel Members of Standardization for Diagnostic Tumor Pathology. Standardization and regulations standardization for diagnostic tumor pathology: gastroenteropancreatic neuroendocrine neoplasm[J]. Zhongguo Bing Li Xue Za Zhi, 2017, 46 (2): 76-8. http://guide.medlive.cn/guideline/12698
[9] 中国临床肿瘤学会神经内分泌肿瘤专家委员会.中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J].临床肿瘤学杂志, 2016, 21(10): 927-36. http://m.medlive.cn/guide/1/12325 Chinese Society of Clinical Oncology Neuroendocrine Tumor Expert Committee. Chinese gastrointestinal pancreatic neuroendocrine tumor expert consensus (2016 version)[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2016, 21(10): 927-36. http://m.medlive.cn/guide/1/12325
[10] 刘恺, 文戈, 邓燕佳, 等.胃类癌动态增强CT表现与病理学对照研究[J].临床放射学杂志, 2012, 31(6): 829-32. http://d.old.wanfangdata.com.cn/Periodical/lcfsxzz201206019 Liu K, Wen G, Deng YJ, et al. Dynamic contrast CT features in gastric carcinoid: Comparative study with pathological findings[J]. Lin Chuang Fang She Xue Za Zhi, 2012, 31(6): 829-32. http://d.old.wanfangdata.com.cn/Periodical/lcfsxzz201206019
[11] Van Binnebeeket S, Vanbilloen B, Baete K, et al. Comparison of diagnostic accuracy of (111)In -pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours[J]. Eur Radiol, 2016, 26(3): 900-9. doi: 10.1007/s00330-015-3882-1
[12] Wang P, Sun B, Huang B, et al. Comparison between percutaneous transhepatic rigid cholangioscopic lithotripsy and conventional percutaneous transhepatic cholangioscopic surgery for hepatolithiasis treatment[J]. Surg Laparosc Endosc Percutan Tech, 2016, 26(1): 54-9. doi: 10.1097/SLE.0000000000000222
[13] Frilling A, ModlinIM, KiddM, et al. Recommendations for management of patients with neuroendocrine liver metastases[J]. Lancet Oncol, 2014, 15(1): e8-21. doi: 10.1016/S1470-2045(13)70362-0
[14] 孟曼, 令狐恩强, 卢忠生, 等.直肠神经内分泌肿瘤内镜下诊治153例分析[J].解放军医学院学报, 2014, 35(6): 558-60. http://d.old.wanfangdata.com.cn/Periodical/jyjxxyxb201406011 Meng M, LingHu EQ, Lu ZS, et al. Endoscopic diagnosis and treatment of rectal neuroendocrine tumor: a report of 153 cases[J]. Jie Fang Jun Yi Xue Yuan Xue Bao, 2014, 35(6): 558-60. http://d.old.wanfangdata.com.cn/Periodical/jyjxxyxb201406011
[15] Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastriointestinal neuroendocrine tumors(nets): well-differentiated nets of the distal colon and rectum[J]. Pancreas, 2010, 39(6): 767-74. doi: 10.1097/MPA.0b013e3181ec1261
[16] 中华医学会肿瘤学分会胰腺癌学组(筹).胰腺神经内分泌肿瘤诊治专家共识[J].中华肿瘤杂志, 2014, 36(9): 717-20. http://m.medlive.cn/guide/1/7133 Pancreatic Cancer Group of the Oncology Branch of Chinese Medical Association. Expert consensus of diagnosis and treatment of pancreatic neuroendocrine tumors[J]. Zhonghua Zhong Liu Za Zhi, 2014, 36(9): 717-20. http://m.medlive.cn/guide/1/7133
[17] Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre-and Perioperative Therapy in Patients with Neuroendocrine Tumors[J]. Neuroendocrinology, 2017, 105(3): 245-54. doi: 10.1159/000461583
[18] 廖彩仙, 周杰, 杨定华, 等.肝胆管结石合并胆汁性肝硬化和门静脉高压症的外科治疗[J].中华肝脏外科手术学电子杂志, 2015, 4(1): 24-6. http://www.cqvip.com/Main/Detail.aspx?id=6974825 Liao CX, Zhou J, Yang DH, et al. Surgical treatments for hepatolithiasis complicated with biliary cirrhosis and portal hypertension[J]. Zhonghua Gan Zang Wai Ke Shou Shu Xue Dian Zi Za Zhi, 2015, 4(1): 24-6. http://www.cqvip.com/Main/Detail.aspx?id=6974825
[19] 王志, 黄秋林.肽受体放射性核素治疗胃肠胰神经内分泌肿瘤[J].现代肿瘤医学, 2017, 25(16): 2685-8. doi: 10.3969/j.issn.1672-4992.2017.16.041 Wang Z, Huang QL. Peptide receptor radionuclide therapy for gastroenteropancreatic neuroendocrine neoplasms[J]. Xian Dai Zhong Liu Yi Xue, 2017, 25(16): 2685-8. doi: 10.3969/j.issn.1672-4992.2017.16.041
[20] Poeppel TD, Boy C, Bockisch A, et al. Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German guideline(S1)[J]. Nuklearmedzin, 2015, 54(1): 1-11. https://www.researchgate.net/publication/272422549_Peptide_receptor_radionuclide_therapy_for_patients_with_somatostatin_receptor_expressing_tumours_German_Guideline_S1
[21] Janson ET, Sorbye H, Welin S, et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J]. Acta Oncol, 2014, 53(10): 1284-97. doi: 10.3109/0284186X.2014.941999
[22] Pavel M, O' Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site[J]. Neuroendocrinology, 2016, 103(2): 172-85. doi: 10.1159/000443167
[23] Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment-'something in the way it moves'[J]. Neuroendocrinology, 2015, 101(4): 263-73. doi: 10.1159/000381930
[24] Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103(2): 153-71. doi: 10.1159/000443171
[25] Seregni E, Ferrai L, Bajetta E, et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2: S69-72. doi: 10.1093/annonc/12.suppl_2.S69
[26] Delle Fave G, O'Toole D, Sundin A, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms[J]. Neuroendocrinology, 2016, 103(2): 119-24. doi: 10.1159/000443168
